Skip to main content
. 2016 Nov 16;9(6):548–556. doi: 10.1016/j.tranon.2016.08.007

Figure 5.

Figure 5

CDK2 inhibitor attenuated tumor growth by increasing radio sensitivity in GBM.

(a) Chemical structure of CDK2 Inhibitor II. (b) In vitro cell viability assay for CDK2 Inhibitor II with 3 GBM cell lines (U138, U251, U87) compared with normal astrocytes (NHA). (c) IC50s of CDK2 Inhibitor II in 3 GBM cell lines (U138, U251, U87) compared with normal astrocytes (NHA). (d) In vitro cell growth assay showed that CDK2 Inhibitor II decreased cell proliferation of U87 when combined with radiation (P < .001, with ELDA analysis). (e) Flow cytometry analysis for apoptosis with Annexin V antibody and Propidium Iodide using U87 cells pretreated with CDK2 Inhibitor II with or without radiation treatment (12 Gy). (f) Representative images of H&E stained mouse brain section after the intracranial transplantation of U87 cells then followed continuously 7-day CDK2 Inhibitor II treatment or placebo by tail vein injection. (g) Kaplan–Meier analysis was performed for the comparison of survival in U87 implanted mice treat with or without CDK2 Inhibitor II (P = .0066, with log-rank test).